Two months into our grant year we have earned 16 cancer treatment credits and 10.7 cancer control credits. To meet our NCI target credits we need to be at 20 treatment and 10 cancer control credits at July’s end. Just a few more treatment credits and we will be on track.

**CRO in Comparison to other CCOP’s for grant year 2010 – 2011**

Below is a table showing CRO credits for the past grant year and how we rank in comparison to the other 62 CCOP/MBCCOP’s in the country.

<table>
<thead>
<tr>
<th>Grant year 2010 - 2011</th>
<th>Treatment Credits</th>
<th>Control Credits</th>
<th>Totals</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRO Credits Assigned by NCI</td>
<td>120</td>
<td>90</td>
<td></td>
</tr>
<tr>
<td>CRO Credits Earned</td>
<td>104.1</td>
<td>63.9</td>
<td></td>
</tr>
<tr>
<td>CRO Total Credits Earned</td>
<td></td>
<td></td>
<td>168</td>
</tr>
<tr>
<td>CRO Percentage Earned</td>
<td>87%</td>
<td>91%</td>
<td>88% or 88.4%</td>
</tr>
<tr>
<td>All 62 CCOP’s Percentage Earned</td>
<td>66%</td>
<td>96%</td>
<td>81%</td>
</tr>
</tbody>
</table>

Overall CRO earned 88.4% of our targeted credits while all CCOP’s averaged 81% of their target credits. Thanks to everyone for your contribution to our success as a CCOP. We do a good job!

**Alliance for Clinical Trials in Oncology Elects Group Chair**

Monica M. Bertagnolli, MD, Chief of Surgical Oncology at Dana-Farber Brigham and Women’s Cancer Center (DF/BWCC), Professor of Surgery at Harvard Medical School and noted clinical and translational researcher, has been elected Group Chair of the newly formed Alliance for Clinical Trials in Oncology (“Alliance”) for a three-year term beginning July 15, 2011. Dr. Bertagnolli, former Cancer and Leukemia Group B (CALGB) Group Chair, has led the CALGB since April 2010, successfully spearheading the merger of three National Cancer Institute-funded cooperative groups (CALGB, North Central Cancer Treatment Group/NCCTG and American College of Surgeons Oncology Group/ACOSOG), which now have formally merged to form the Alliance.

**SWOG Request Input for Breast Trials**

SWOG Breast Committee is interested in identifying clinically relevant questions in the management of primary and metastatic breast cancer that are worthy of developing into clinical trials. They believe that the clinicians who treat breast cancer on a daily basis are a potential source of ideas for clinical trials. If you have ideas you wish to share please contact David A. Decker, MD at David.Decker.MD@flhosp.org or 407-303-2000. Below is an email with more details. Staff at CRO will be happy to assist you with your idea submissions as well. Contact us at 269-4520.
SWOG Request Input for Breast Trials Email
The Working Group of the SWOG Breast Committee is interested in identifying clinically relevant questions in the management of primary and metastatic breast cancer that are worthy of developing into clinical trials. We believe that the clinicians who treat breast cancer on a daily basis are a potential source of ideas for clinical trials. We believe that an excellent source of ideas is the clinical investigators of the CCOPs, as indeed your CCOP investigators may have identified several clinically relevant issues. This source of ideas has heretofore gone unrecognized, and the Breast Committee leadership wishes to give the breast cancer clinicians a voice for their observations with the hope that these observations may lead to clinical trials within SWOG. Clinically relevant issues could be found in breast cancer prevention, treatment, survivorship, or quality of life, and they might originate from medical, surgical, or radiation oncologists.

I would ask you to forward this e-mail to those members of your CCOP that you believe may have breast cancer related relevant issues. If relevant questions are identified, I would ask the proponent to contact me (David.Decker.MD@flhosp.org) with her/his proposed topic, as well as the name and e-mail address. I plan to arrange a web-cast/phone conference or face-to-face meeting during the fall SWOG meeting to review and prioritize the clinical issues brought up by our members. At this web-cast/phone conference or meeting there will be representatives of the Working Group. For those who are intimidated by any formal process, please call me directly and we can discuss your ideas privately.

David A. Decker, MD, FACP
Executive Director Florida Hospital Cancer Institute
Professor of Internal Medicine, University of Central Florida
2501 North Orange Avenue, Suite 289
Orlando Florida 32804
Fax: 407-303-2009
E-mail: David.Decker.MD@flhosp.org

New Studies Approved in July 2011

Opened at Cox

CTSU ECOG E2108 A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
GOG-0227G A Phase II Evaluation of Brivanib (IND #108417) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
SWOG S0820 A Double Blind Placebo-Controlled Trial of Efornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III
SWOG S0931 EVERST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Opened at St. John’s

NCCTG N08C9 Phase III, Randomized Study of Sulfasalazine versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy

Studies Permanently Closed to Enrollment at Cox & St. John’s in July 2011

CTSU NCCTG N063D ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study: A Randomised, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer
SWOG S8819 Central Lymphoma Repository Tissue Procurement Protocol

Permanently Closed @ Cox:
ChemoFX A non-interventional, longitudinal, multi-center initiative examining outcomes associated with the use of the ChemoFx Assay® in solid tumor malignancies

Partial Closure at Cox & St. John’s

SWOG S0802 A Randomized Phase II Trial of Weekly Topotecan with and without AVE0005 (Aflibercept; NSC-724770) in Patients with Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC) The platinum sensitive stratum remains open